Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy - 18 Oct 2022

Pi Rui, Chen Xiaomin, Meng Jian, Liu Qingyun, Chen Yiwang, Bei Cheng, Wang Chuan, Gao Qian

Abstract excerpt

Contezolid (MRX-I), a safer antibiotic of the oxazolidinone class, is a promising new antibiotic with potent activity against Mycobacterium tuberculosis (MTB) both in vitro and in vivo. To identify resistance mechanisms of contezolid in MTB, we isolated several in vitro spontaneous contezolid-resistant MTB mutants, which exhibited 16-fold increases in the MIC of contezolid compared with the parent strain but were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Flavins

Share to Linezolid

Share to Microbial Sensitivity Tests

Share to Mixed Function Oxygenases

Share to Mycobacterium tuberculosis

Share to Oxazolidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 36190243
DOI: 10.1128/aac.01034-22
PMCID: PMC9578412

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.PMID 36190243Read ↗

Drug degradation caused by <i>mce3R</i> mutations confers contezolid (MRX-I) resistance in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisSemantic proximity Read ↗

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisSemantic proximity Read ↗

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosisSemantic proximity Read ↗

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In VitroSemantic proximity Read ↗

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in ChinaSemantic proximity Read ↗

Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus.Semantic proximity Read ↗

Mechanisms of Linezolid Resistance in MycobacteriaSemantic proximity Read ↗

Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China.Semantic proximity Read ↗

Comparative In Vitro Drug Susceptibility Study of Five Oxazolidinones Against Mycobacterium tuberculosis in Hainan, ChinaSemantic proximity Read ↗

Delamanid Resistance: Update and Clinical ManagementSemantic proximity Read ↗

<i>In Vitro</i> efficacy comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.